Biopharma & Life Sciences
UroGen Pharma Executive Compensation (FY25)
URGN · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): June 23, 2026
124 figures on this page: 116 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Total compensation for Elizabeth Barrett, President and Chief Executive Officer, came to $4,310,624 in fiscal 2025, and Barrett's total was 3.9% higher than the $4,149,858 reported for fiscal 2024. Meanwhile, the say-on-pay proposal drew 88.8% support at the meeting held June 23, 2026 for fiscal 2025. Separately, the disclosed peer group includes Arcus Biosciences, Arvinas, Aura Biosciences, C4 Therapeutics and Day One Biopharmaceuticals, among others. The company reported 3 named executive officers for fiscal 2025.
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Elizabeth Barrett: $4,149,858 → $4,310,624 (3.9% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is UroGen Pharma's chief executive and what were they paid?
Total compensation for Elizabeth Barrett, President and Chief Executive Officer, came to $4,310,624 in fiscal 2025. Barrett's total was 3.9% higher than the $4,149,858 reported for fiscal 2024.
What was UroGen Pharma's say-on-pay result?
The say-on-pay proposal drew 88.8% support at the meeting held June 23, 2026 for fiscal 2025.
Which companies are in UroGen Pharma's peer group?
The disclosed peer group includes Arcus Biosciences, Arvinas, Aura Biosciences, C4 Therapeutics and Day One Biopharmaceuticals, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Elizabeth Barrett Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Smith General Counsel and Chief Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Elizabeth Barrett President and Chief Executive Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Smith General Counsel and Chief Compliance Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Mark Schoenberg Chief Medical Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Elizabeth Barrett | OTHER | — | — | — | — | — | — | ◇ |
| Jason Smith | OTHER | — | — | — | — | — | — | ◇ |
| Mark Schoenberg | OTHER | — | — | — | — | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mark Schoenberg | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Elizabeth Barrett | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Jason Smith | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Arie Belldegrun, M.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Leana S. Wen, M.D., M.Sc | ◇ | ◇ | ◇ | — | — | — | ◇ |
Cynthia M. Butitta | ◇ | ◇ | ◇ | — | — | — | ◇ |
James A. Robinson, Jr | ◇ | ◇ | ◇ | — | — | — | ◇ |
Stuart Holden, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Daniel G. Wildman and Elizabeth Barrett served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Arcus Biosciences RCUS
- Arvinas ARVN
- Aura Biosciences AURA
- C4 Therapeutics CCCC
- Day One Biopharmaceuticals DAWN
- Erasca ERAS
- IDEAYA Biosciences IDYA
- iTeos Therapeutics ITOS
- Kura Oncology KURA
- Olema Pharmaceuticals OLMA
- Rigel Pharmaceuticals RIGL
- Sutro Biopharma STRO
- Syndax Pharmaceuticals SNDX
- Tango Therapeutics TNGX
- Tyra Biosciences TYRA
- Xencor XNCR
- Y-mAbs Therapeutics YMAB
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 23, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | August 27, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | August 8, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | September 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 8, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 7, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 8, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 3, 2019 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact UroGen Pharma disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where UroGen Pharma sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
124 figures on this page: 116 cited to the filing that reported them, 8 calculated from figures it prints.
116 cited to the filing
8 calculated from the filing
Documents cited
- 0001437749-26-021442Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001437749-26-0142372025 Outstanding Equity Awards at Fiscal Year End Table · Director Compensation · EXECUTIVE COMPENSATION & · Non-Employee Director Compensation · and 1 more section
- 0001437749-25-027874Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001437749-25-022732Summary Compensation Table
- 0001193125-24-197008Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-23-232477Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001437749-22-014892Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-032093Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-165697Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-168284
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “UroGen Pharma executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/URGN (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about UroGen Pharma and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers UroGen Pharma discloses
The companies named in URGN's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}